Luminus Management’s Core Laboratories CLB Stock Holding History

Luminus Management’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-599,166	Closed	-$6.2M	–	53
2020 Q1	$6.2M	Buy	+599,166	New	+$16.8M	0.64%	48

Other funds holding CLB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Luminus Management's CLB Position: Q2 2020 in Review

Luminus Management sold out of Core Laboratories (CLB) in Q2 2020, closing a stake of 599,166 shares — an estimated $6.2M sold.

Luminus Management first reported a position in CLB in Q1 2020 and held it in 1 quarter. The position peaked at $6.2M in Q1 2020. 197 funds tracked by Wall St. Rank hold CLB as of Q2 2020.

Luminus Management reported no remaining Core Laboratories position as of Q2 2020 after selling out during the quarter.
Luminus Management sold 599,166 Core Laboratories shares in Q2 2020, an estimated $6.2M.
Luminus Management first reported a position in Core Laboratories in Q1 2020 and held it in 1 quarter.
Luminus Management's Core Laboratories position peaked at $6.2M in Q1 2020.
197 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2020.

Based on Luminus Management's 13F filing for Q2 2020, filed 14 Aug 2020.